[
    {
        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "MEf5YGvLKJmJtbW1tRC/Wjk2424dj2de1+sLXDHG8I2BnwFOytNEaFYuIPD/ag5SFZaoW5s/4nVuh0cEVLDmTf7OJdIosAm6i5KO4oo8/oZsmTKpJncczV0eygSBtfxtXvpnQ/6zUt+mu0qDyMCdh3BuqJn774r70W83WNTuPv0="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-06-19T08:33:46.235+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_3310",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAgGfWvIP7ymf3ZmSss5MexcCaF4Vqe6yvzT4lVHxHsjE#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_3310"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB00337"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "pimecrolimus cream 1 is indicated as second line therapy for the short term and non continuous chronic treatment of mild to moderate atopic dermatitis in non immunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable pimecrolimus cream 1 is not indicated for use in children less than 2 years of age warnings and precautions 5 1 use in specific populations 8 4 pimecrolimus cream 1 is a calcineurin inhibitor immunosuppressant indicated as second line therapy for the short term and non continuous chronic treatment of mild to moderate atopic dermatitis in non immunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable 1"
                    }
                ],
                "https://w3id.org/biolink/vocab/association_type": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/TreatmentIndication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB00337",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]